Publications by authors named "Ioannis Sofroniadis"
Article Synopsis
- Gamma-irradiation leads to cell death (apoptosis) and stops cell division (cell cycle arrest) in eukaryotic cells, specifically affecting the G2 phase.
- Olomoucine, a new drug that inhibits certain proteins (cyclin-dependent kinases), was studied in the Raji cell line for its effects on cells treated with gamma-irradiation.
- The combination of olomoucine and gamma-irradiation intensified cell cycle arrest and reduced survival rates, while also delaying the apoptotic process but hindering cell growth and DNA synthesis in remaining cells.
Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial.
Int J Radiat Oncol Biol Phys
July 2004
Purpose: Tumor volume (TV) is one of the main reported factors determining the outcome of treatment in head-and-neck carcinomas. In this study, the prognostic impact of TV was explored in the context of a randomized trial with the patients assigned to receive standard radiotherapy (RT) alone or RT plus platinum compounds (RT alone, RT plus cisplatin, or RT plus carboplatin).
Methods And Materials: The tumor outlines were traced and digitized on each pretreatment CT slice for each of the 101 patients studied.
Primary tumors of the spine are relatively infrequent lesions compared with metastatic disease, multiple myeloma, and lymphoma. A wide variety of benign and malignant neoplasms can involve the spine. The imaging features of these lesions are often characteristic.
View Article and Find Full Text PDFBackground And Aim: While octreotide has been used in palliative treatment of hepatocellular carcinoma and neuroendocrine tumours with good results, little is known about the possible role of this in palliative treatment of hepatic metastases.
Material And Methods: We present our experience from the use of octreotide in palliative treatment of symptomatic liver metastases in 16 patients (11 males, five females, age ranged 43-69 years) with proven hepatic metastases from different primary tumours (six with non-small lung cancer, four with colon carcinoma, two with primary pancreatic head carcinoma, two with prostate cancer and two with adenocarcinoma of the stomach). All patients were administered 20 mg long-acting octreotide IM (octreotide LAR) once the first day, octreotide SC 0.